

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report
Fiscal Year 2020 (7/1/2019 to 6/30/2020)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - Bloomington

	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board								
New Studies - Full Board (to review)	14.0	14.0	26.6	28.0	19.2	26.0	20.2	19.5
New Studies - Full Board (to approval)	n/a	n/a	36.1	41.0	65.8	56.0	35.3	35.3
Exempt								
New Studies - Exempt (to determination)	9.0	10.6	13.0	13.0	29.25	22.5	26.3	29.0
Amendments								
Amendments - Minor	4.4	2.0	2.4	0.5	4.3	1.0	2.1	0.0
Amendments - Major	11.6	11.0	17.3	7.0	17.7	14.0	30.1	32.0

*Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	1	0	-1 (100.0%)	8	4	-4 (50.0%)	5	4	-1 (20.0%)	8	4	-4 (50.0%)
New Studies - Exempt	4	5	1	3	1	-2 (66.7%)	8	8	0	4	4	0
Amendments - Minor	52	66	14	40	42	2	32	32	0	24	23	-1 (4.2%)
Amendments - Major	3	5	2	2	3	1	9	6	-3 (33.3%)	7	9	2
Continuing Reviews	29	42	13	29	33	4	23	23	0	27	26	-1 (3.7%)
TOTAL	89	118	29 (-32.6%)	82	83	1 (-1.2%)	77	73	-4 (5.2%)	70	66	-4 (5.7%)

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	1	0	0	0	1

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	0	0	0	0
30 Day OBA Report	0	1	0	0	1
Lab Accident/Injury/Exposure	0	1	0	0	1

Reporting Agency: NIH Office of Biotechnology Activities (OBA)